Onkologie. 2019:13(6):273-277
Head and Neck Cancer Immunotherapy
- Komplexní onkologické centrum, Nemocnice Nový Jičín, a. s.
Immunotherapy represents a perspective treatment modality which has quickly established its position in several tumor types. Due to the high mutation burden of head and neck tumors there was an assumption of immunotherapy efficacy. The phase I clinical trials were in line with these preclinical assumptions and phase II and III trials have confirmed the effectivity of nivolumab in second palliative lines and in the case of pemrolizumab as weel as in the first palliative line of recurrent and methastatic head and neck cancer where they have showed superiority over current treatment standards. Unfortunatelly, at this moment despite ongoing registrations in this indication the insurance reimbursement is lacking so far.
Keywords: immunotherapy, head and neck cancer, chemotherapy
Published: December 1, 2019 Show citation
